|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.4 CAD | +11.11% |
|
+1.27% | -17.53% |
| Apr. 26 | BioNxt Solutions Inc. Announces ODF Cladribine Update | CI |
| Apr. 26 | BioNxt Solutions Inc. announced that it expects to receive CAD 1.62 million in funding | CI |
BioNxt Solutions Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was CAD 0.297442 million compared to CAD 0.286498 million a year ago. Net loss was CAD 12.38 million compared to CAD 20.64 million a year ago.
Basic loss per share from continuing operations was CAD 0.15 compared to CAD 0.29 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -17.53% | 32M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
BIONXT SOLUTIONS INC. 
